drugset / Trial / NCT00125203

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00125203

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.

Timeline

Start
2003-07
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum Toxin Type B Unknown Other